The structural basis for Ras activation of PI3Kα lipid kinase†

Mingzhen Zhang, c Hyunbum Jang, a and Ruth Nussinov b,c,d

PI3Kα is a principal Ras effector that phosphorylates PIP2 to PIP3 in the PI3K/Akt/mTOR pathway. How Ras activates PI3K has been unclear: is Ras’ role confined to PI3K recruitment to the membrane or does Ras activation also involve allostery? Recently, we determined the mechanism of PI3Kα activation at the atomic level. We showed the vital role and significance of conformational change in PI3Kα activation. Here, by a ‘best-match for hydrogen-bonding pair’ (BMHP) computational protocol and molecular dynamics (MD) simulations, we model the atomic structure of KRas4B in complex with the Ras binding domain (RBD) of PI3Kα, striving to understand the mechanism of PI3Kα activation by Ras. Point mutations T208D, K210E, and K227E disrupt the KRas4B–RBD interface in the models, in line with the experiments. We identify allosteric signaling pathways connecting Ras to RBD in the p110α subunit. However, the observed weak allosteric signals coupled with the detailed mechanism of PI3Kα activation make us conclude that the dominant mechanistic role of Ras is likely to be recruitment and restriction of the PI3Kα population at the membrane. Thus, RTK recruits the PI3Kα to the membrane and activates it by relieving its autoinhibition exerted by the nSH2 domain, leading to exposure of the kinase domain, which permits PIP2 binding. Ras recruitment can shift the PI3Kα ensemble toward a population where the kinase domain surface and the active site position and orientation favor PIP2 insertion. This work helps elucidate Ras-mediated PI3K activation and explores the structural basis for Ras–PI3K drug discovery.

PI3Kα is an obligate heterodimer, which includes the p85α regulatory subunit and p110α catalytic subunit. Their interactions stabilize the overall structure and keep PI3Kα in the inactive state. The N-terminal SH2 domain (nSH2 domain) in the p85α regulatory subunit plays the dominant role in PI3Kα activation. The phosphorylated tyrosine (pY) motifs in the receptor tyrosine kinases (RTKs) possess high affinity to the nSH2 domain. It recruits PI3Kα to the membrane and activates it by releasing the nSH2 domain from the p110α catalytic subunit. Calmodulin (CaM) also targets SH2 domains, recruits and activates PI3Kα by a similar mechanism. The nSH2 release promotes PI3Kα membrane interaction and increases its activity. We recently determined the atomic-level mechanism of PI3Kα activation, which emphasizes the critical role of the conformational change in the activation. Upon nSH2 release, the C-lobe of the kinase domain moves away from the C2 domain, making the PI3Kα membrane binding surface more exposed for the membrane interactions. The activation loop in the kinase domain becomes more conformational change in the activation.

Ras is a key PI3Kα activator. Its catalytic domain binds effectors and the disordered hypervariable region (HVR) anchors, and can regulate, Ras attachment to the membrane.
contains the hydrophobic palmitoyl motif, farnesyl motif or both, depending on the type of Ras isoform. Ras activates PI3K by promoting its membrane recruitment and gathering the PIP2 substrate. A single-molecule study showed that HRas interactions inhibit the activity of the membrane-bound, pY-activated PI3K, indicating that the role of Ras in PI3K activation is not confined to promoting membrane interactions. Ras recognizes the RBD of PI3K. The crystal structure of Ras–PI3K shows that HRas recognizes the PI3K’s RBD through the antiparallel β-sheet interactions and the surrounding residue contacts.

Despite its significance, the structural basis for PI3K activation by Ras has been elusive. Initial attempts to characterize the Ras–PI3K complex by crystallography have been unsuccessful, probably due to the high structural complexity of PI3K and the low Ras–PI3K binding affinity. Biochemical and in vivo data have helped uncover key residues at the Ras–PI3K interface, including K227 and T208 in the RBD of PI3K. Their mutations reduce the Ras–RBD interactions in vitro and in vivo but in the absence of structure, exactly how has been unclear. Further, the absence of a structure left the question of how Ras activates PI3K unresolved.

Here, we modeled the atomic structure of KRas4B binding to the RBD of PI3K by a best-match for hydrogen-bonding pair (BMHP) computational protocol and molecular dynamics (MD) simulations, striving to understand PI3K activation by Ras. Different from Raf’s activation which requires the kinase domain dimerization via a Ras dimer or nanocluster, PI3K activation is through single Ras interaction with single RBD. KRas4B shares a general scenario in recognizing PI3K via antiparallel β-sheet interactions but differs in the interfacial residue contacts. The modeled KRas4B–RBD structure exhibited a high structural stability in the simulation and was disrupted by the experimentally-verified mutations. We observed allosteric pathways from KRas4B to PI3K–RBD, albeit presenting weak, likely biologically irrelevant signals.

This suggests a scenario where membrane-anchored Ras recruits PI3K to the membrane. RTK also recruits PI3K to the membrane. RTK’s phosphorylated motifs at the C-terminal relieve the autoinhibition exerted by the nSH2 domain of the p85α, exposing the catalytic site for the PIP2 substrate to bind. However, the population with the active site favorably positioned and oriented for substrate binding may fluctuate and be limited. Ras binding to the RBD may serve to recruit, restrict and shift the PI3K ensemble, promoting a preorganized PIP2-binding-favored state. Because the differences in stabilities between autoinhibited and active states are often relatively small, drugging these states can be challenging. This work provides the atomic-level structural and dynamic basis for physiological and mutant PI3K activation, and thereby deeper understanding of Ras-mediated PI3K/Akt/mTOR signaling and drug discovery targeting the Ras–PI3K interactions.

Results

Modeling of the KRas4B–PI3Kα–RBD complex

Ras is a small GTPase, regulating multiple cellular signaling pathways via downstream effectors including Raf in the Raf/MEK/ERK pathway, RalGDS in the RalGDS/Ral pathway, and PI3K in the PI3K/Akt pathway. Ras recognizes its effectors via the highly homologous RBDs. The antiparallel β-sheet interaction is the signature structural feature at the Ras–effector interface. The β2 region of Ras interacts with the exposed β-strand of RBD in effectors, forming intermolecular backbone hydrogen bonds (H-bonds). Like other Ras effectors, PI3K contains the typical RBD for Ras recognition, with the structure resembling other Ras effectors (Raf, RalGDS, PI3Kα, etc.). Thus, antiparallel β-sheet interactions are expected at the interface between Ras and RBD of PI3K. Ras uses E37 and S39 for Raf recognition, E37, S39 and R41 for RalGDS recognition, and E37, S39, and R41 for PI3Kα recognition at the antiparallel β-sheet interface. Here, we developed the BMHP protocol to provide possible modes of H-bond formations at the interface of KRas4B with PI3Kα–RBD. This protocol systematically screened the antiparallel β-sheet interface by sliding the residue pairs and performed a series of optimization for the H-bond pairs. Both KRas4B and PI3Kα–RBD contain the hydrophobic palmitoyl motif, farnesyl motif or both, depending on the type of Ras isoform. The crystal structure of Ras–PI3K shows that HRas recognizes the PI3K’s RBD through the antiparallel β-sheet interactions and the surrounding residue contacts.

Despite its significance, the structural basis for PI3K activation by Ras has been elusive. Initial attempts to characterize the Ras–PI3K complex by crystallography have been unsuccessful, probably due to the high structural complexity of PI3K and the low Ras–PI3K binding affinity. Biochemical and in vivo data have helped uncover key residues at the Ras–PI3K interface, including K227 and T208 in the RBD of PI3K. Their mutations reduce the Ras–RBD interactions in vitro and in vivo but in the absence of structure, exactly how has been unclear. Further, the absence of a structure left the question of how Ras activates PI3K unresolved.

Here, we modeled the atomic structure of KRas4B binding to the RBD of PI3K by a best-match for hydrogen-bonding pair (BMHP) computational protocol and molecular dynamics (MD) simulations, striving to understand PI3K activation by Ras. Different from Raf’s activation which requires the kinase domain dimerization via a Ras dimer or nanocluster, PI3K activation is through single Ras interaction with single RBD. KRas4B shares a general scenario in recognizing PI3K via antiparallel β-sheet interactions but differs in the interfacial residue contacts. The modeled KRas4B–RBD structure exhibited a high structural stability in the simulation and was disrupted by the experimentally-verified mutations. We observed allosteric pathways from KRas4B to PI3K–RBD, albeit presenting weak, likely biologically irrelevant signals.

This suggests a scenario where membrane-anchored Ras recruits PI3K to the membrane. RTK also recruits PI3K to the membrane. RTK’s phosphorylated motifs at the C-terminal relieve the autoinhibition exerted by the nSH2 domain of the p85α, exposing the catalytic site for the PIP2 substrate to bind. However, the population with the active site favorably positioned and oriented for substrate binding may fluctuate and be limited. Ras binding to the RBD may serve to recruit, restrict and shift the PI3K ensemble, promoting a preorganized PIP2-binding-favored state. Because the differences in stabilities between autoinhibited and active states are often relatively small, drugging these states can be challenging. This work provides the atomic-level structural and dynamic basis for physiological and mutant PI3K activation, and thereby deeper understanding of Ras-mediated PI3K/Akt/mTOR signaling and drug discovery targeting the Ras–PI3K interactions.

Results

Modeling of the KRas4B–PI3Kα–RBD complex

Ras is a small GTPase, regulating multiple cellular signaling pathways via downstream effectors including Raf in the Raf/MEK/ERK pathway, RalGDS in the RalGDS/Ral pathway, and PI3K in the PI3K/Akt pathway. Ras recognizes its effectors via the highly homologous RBDs. The antiparallel β-sheet interaction is the signature structural feature at the Ras–effector interface. The β2 region of Ras interacts with the exposed β-strand of RBD in effectors, forming intermolecular backbone hydrogen bonds (H-bonds). Like other Ras effectors, PI3K contains the typical RBD for Ras recognition, with the structure resembling other Ras effectors (Raf, RalGDS, PI3Kα, etc.). Thus, antiparallel β-sheet interactions are expected at the interface between Ras and RBD of PI3K. Ras uses E37 and S39 for Raf recognition, E37, S39 and R41 for RalGDS recognition, and E37, S39, and R41 for PI3Kα recognition at the antiparallel β-sheet interface. Here, we developed the BMHP protocol to provide possible modes of H-bond formations at the interface of KRas4B with PI3Kα–RBD. This protocol systematically screened the antiparallel β-sheet interface by sliding the residue pairs and performed a series of optimization for the H-bond pairs. Both KRas4B and PI3Kα–RBD contain the hydrophobic palmitoyl motif, farnesyl motif or both, depending on the type of Ras isoform. The crystal structure of Ras–PI3K shows that HRas recognizes the PI3K’s RBD through the antiparallel β-sheet interactions and the surrounding residue contacts.

Despite its significance, the structural basis for PI3K activation by Ras has been elusive. Initial attempts to characterize the Ras–PI3K complex by crystallography have been unsuccessful, probably due to the high structural complexity of PI3K and the low Ras–PI3K binding affinity. Biochemical and in vivo data have helped uncover key residues at the Ras–PI3K interface, including K227 and T208 in the RBD of PI3K. Their mutations reduce the Ras–RBD interactions in vitro and in vivo but in the absence of structure, exactly how has been unclear. Further, the absence of a structure left the question of how Ras activates PI3K unresolved.

Here, we modeled the atomic structure of KRas4B binding to the RBD of PI3K by a best-match for hydrogen-bonding pair (BMHP) computational protocol and molecular dynamics (MD) simulations, striving to understand PI3K activation by Ras. Different from Raf’s activation which requires the kinase domain dimerization via a Ras dimer or nanocluster, PI3K activation is through single Ras interaction with single RBD. KRas4B shares a general scenario in recognizing PI3K via antiparallel β-sheet interactions but differs in the interfacial residue contacts. The modeled KRas4B–RBD structure exhibited a high structural stability in the simulation and was disrupted by the experimentally-verified mutations. We observed allosteric pathways from KRas4B to PI3K–RBD, albeit presenting weak, likely biologically irrelevant signals.

This suggests a scenario where membrane-anchored Ras recruits PI3K to the membrane. RTK also recruits PI3K to the membrane. RTK’s phosphorylated motifs at the C-terminal relieve the autoinhibition exerted by the nSH2 domain of the p85α, exposing the catalytic site for the PIP2 substrate to bind. However, the population with the active site favorably positioned and oriented for substrate binding may fluctuate and be limited. Ras binding to the RBD may serve to recruit, restrict and shift the PI3K ensemble, promoting a preorganized PIP2-binding-favored state. Because the differences in stabilities between autoinhibited and active states are often relatively small, drugging these states can be challenging. This work provides the atomic-level structural and dynamic basis for physiological and mutant PI3K activation, and thereby deeper understanding of Ras-mediated PI3K/Akt/mTOR signaling and drug discovery targeting the Ras–PI3K interactions.
solely mediated by the molecular interface; instead, structural ensembles and monomer dynamics may be at play, which, in part, explain the low Kras4B–RBD binding affinity. To eliminate the collapse, we conducted short molecular dynamics (MD) simulations with external constraints on the backbone H-bonds at the antiparallel β-sheet interface. Explicit-solvent all-atom MD simulations were then performed to evaluate their structural and energetic validity. In the simulations, four of the five Kras4B–RBD models (models 1, 2, 4, and 5) lost their interfaces, while model 3 showed excellent structural stability (Fig. 1C). We further enhanced the sampling by generating more systems with different initial atom velocities and ran additional 8 μs simulations (details can be found in Method and materials section). The overall structure and the antiparallel β-sheet interface of model 3 were maintained in a total of ~10.4 μs simulations.

**Model 3 initially had six backbone H-bonds at S39KRas4B–T208PI3Kα, R41KRas4B–K206PI3Kα, and Q43KRas4B–K204PI3Kα at the antiparallel β-sheet interface. Three of them at S39KRas4B–T208PI3Kα and R41KRas4B–K206PI3Kα, remained stable in the simulations, while the other three disappeared (Fig. 2A). A backbone H-bond also formed between E37KRas4B and K210PI3Kα due to the structural adjustment.** The Switch I region of Ras shows a significant contribution to the Kras4B–RBD interface interaction. The exposed acidic residues (D30, E31, D33, and D38) in the Switch I region of Kras4B form a long negatively-charged surface, to which the basic residues in PI3Kα–RBD interacted with at least one of the two acidic residues (D33 and D38) in Kras4B.

**Key point mutations at the Kras4B–PI3Kα–RBD interface**

To verify the model, we tested mutations in the PI3Kα–RBD and explored their roles in Kras4B–RBD recognition. The first mutation was at K227PI3Kα. This mutation in PI3Kα–RBD, with charge reversal, has been shown to eliminate the Ras–PI3Kα interactions in vitro. The mutation also resulted in perinatal lethality in mouse with reduced PI3K/Akt/mTOR signals. We introduced the K227E mutation into Kras4B–PI3Kα–RBD complex and performed the simulations. In the wild-type Kras4B–RBD structure, K227PI3Kα formed a dual salt bridge with D33Kras4B and D38Kras4B at the interface. The K227E mutation in PI3Kα–RBD resulted in repulsive forces to Kras4B Switch I region and disrupted the Kras4B–RBD interface in the simulation (Fig. 4A).

The mutation T208D in PI3Kα–RBD showed a similar in vivo effect as K227E. It caused significant disorder in vivo, disrupting the PI3K/Akt/mTOR signaling in mouse, a hydrophilic residue located at the β2 strand of PI3Kα–RBD. Its backbone formed key H-bonds with Kras4B at the antiparallel β-sheet interface (S39Kras4B–T208PI3Kα). When T208 was mutated to negatively charged D208PI3Kα, its side-chain formed electrostatic interactions with the adjacent residue K206PI3Kα. This led to a pronounced structural change at the β2 region of PI3Kα–RBD (Fig. S1, ESI†). The bent conformation became flat. This disrupted the antiparallel β-sheet interface and eventually destroyed the Kras4B–PI3Kα–RBD complex in the simulation (Fig. 4B).

The mutations at K227E and T208D in PI3Kα–RBD individually emphasized the importance of the interfacial salt bridges and β-sheet interactions in Kras4B–RBD recognition. We further eliminated the other three salt bridges (D30Kras4B–R230PI3Kα, E31Kras4B–R230PI3Kα, and E37Kras4B–K210PI3Kα) by mutating residues K210 and R230 in PI3Kα–RBD, exploring their roles in stabilizing the Kras4B–RBD interface. As expected, the mutation of PI3Kα at K210E disrupted the Kras4B–RBD interface in the simulation (Fig. 4C). However, the Kras4B–PI3Kα–RBD complex with the R230E mutation maintained its overall structural integrity through the 1 μs simulation, indicating that it is not as important for the Kras4B–RBD interface as other interfacial residues (Fig. S2, ESI†). This is in line with its low stability in the Kras4B–PI3Kα–RBD complex (Fig. 3F).

**Allosteric signaling may propagate from Kras4B to PI3Kα**

Ras activates PI3Kα and promotes PI3K/Akt signaling. Full activation of PI3Kα requires the release of autoinhibition
(release of nSH2) and enhanced membrane localization. 35 In PI3Kα, RBD connects to the helical domain (the domain mediating nSH2 autoinhibition), and the kinase domain (the domain that executes substrate catalysis). We performed weighted implementation of suboptimal path (WISP) analysis39 and identified multiple allosteric signaling pathways from KRas4B to PI3Kα–RBD (Fig. 5). The allosteric signaling pathways go through the antiparallel β-sheet interface, ending at the α-helix region (residue 265–280) in RBD. KRas4B residues S39, Y40, R41 and PI3Kα residues V192, V193, I194, Y207, T208, M278, L279, G280, R281, M282, P283 are in the allosteric pathways. The α-helix region in RBD connects to the C-lobe of the kinase domain in PI3Kα, and links to the helical domain via a random coil. This indicates that Ras may deliver allosteric signals to these domains via RBD. The helical domain is the main domain that accommodates the nSH2 domain of the p85α regulatory subunit. Its dynamics, which may be affected by the KRas4B, is crucial for the release of nSH2 in PI3Kα autoinhibition. The kinase domain in the p110 subunit catalyzes the reaction. We have shown that upon nSH2 release, the C-lobe of the kinase domain moved away from the C2 domain and became more accessible for membrane interactions.16 However
the absence of observable RBD conformational change, coupled with the body of the experimental\textsuperscript{10} and computational results\textsuperscript{16} lead us to conclude that even though it may assist in PI3K activation, that contribution is likely to be minor.

**Discussion**

PI3K\textalpha is one of the primary Ras effectors.\textsuperscript{40} Its frequent mutations drive cancer.\textsuperscript{41–43} Despite its paramount significance in signaling and cancer drug discovery, the structural basis for PI3K\textalpha activation by Ras has been elusive.\textsuperscript{44,45} Exploiting the BMHP protocol and MD simulations, we modeled the atomic structure of the KRas4B–PI3K\textalpha–RBD complex, with properties in line with experiments. The antiparallel \(\beta\)-sheet interactions mediate the overall structural stability of the Ras–PI3K\textalpha complex, and the salt bridges formed by the Switch I region in KRas4B with the RBD of PI3K\textalpha contribute significantly to the Ras–PI3K\textalpha interface. Ras follows a similar PI3K\textalpha recognition scenario but differs in the interfacial residue contacts. Ras interacts with both PI3K\textbeta and PI3K\textgamma via the interfacial antiparallel \(\beta\)-sheet interactions and the extensive surrounding residue contacts.\textsuperscript{31} The structural alignment indicates that Ras employs identical residues (E37, S39, and R41) for the antiparallel \(\beta\)-sheet interactions with PI3K\textalpha and PI3K\textbeta. Although the \(\alpha\) region in PI3K\textgamma’s RBD is shorter than PI3K\textalpha, the antiparallel \(\beta\)-sheet interactions occur at the similar area (Fig. 6A). While the antiparallel \(\beta\)-sheet interactions show remarkable similarity, the surrounding residue contacts are different. This is largely due to sequence differences in RBD’s \(\beta\)-sheet region and structural differences in \(\beta\)2 region (Fig. 6B).

Notably, the interactions between Switch II region of HRas with PI3K\textgamma’s RBD (E63\textsuperscript{HRas}–K234\textsuperscript{PI3K\textgamma}) were not observed in the KRas4B–PI3K\textbeta–RBD structure. However, when we modeled KRas4B into the full PI3K\textbeta, the salt bridge (R73\textsuperscript{KRas4B}–E888\textsuperscript{PI3K\textbeta}) was formed between Switch II region of KRas4B and the C-lobe of kinase domain in PI3K\textbeta (Fig. 6C and D).

The Ras family of proteins includes the HRas, NRas and KRas (KRas4A and KRas4B) isoforms.\textsuperscript{28,46} All bind to PI3K\textalpha.\textsuperscript{47,48} Ras isoforms share high sequence identity (~80%). In this work, we selected KRas4B to explore the structural basis for PI3K\textalpha activation by Ras, because of its frequent expression and thus significance in over-activating PI3K\textalpha in cancer.\textsuperscript{49–51} The isoform-specific residues in Ras are all far away from the KRas4B–RBD interface, raising the possibility that these residues may have allosteric effects, albeit likely insignificant, since most of these isoform-specific residues are exposed on the Ras surface.\textsuperscript{54} Thus, the structure solved in this work is expected to represent a general Ras–PI3K\textalpha interaction scenario.

Ras has frequent oncogenic mutations at G12.\textsuperscript{55} The cancer-driven mutations at G12 promote PI3K signaling but did not appear at the Ras–PI3K\textalpha interface.\textsuperscript{56,57} We ran simulations of the KRas4B–PI3K\textalpha–RBD complex with the G12D mutation and did not observe significant change at the KRas4B–RBD interface. Since the G12 mutation stabilizes the Switch I region of Ras and tends to allosterically release the HVR from the catalytic domain,\textsuperscript{48,58,59} it can promote Ras–PI3K\textalpha recognition.

Ras is a membrane-attached protein with a hydrophobic HVR. The interaction of PI3K\textalpha with Ras promotes its membrane localization, making PI3K\textalpha more accessible to its lipid substrate.\textsuperscript{6} The RBD, to which Ras binds, connects to the helical and kinase domains in PI3K\textalpha. Two domains are individually crucial for PI3K\textalpha’s autoinhibition and catalysis. The helical domain is the main domain in the p110\textalpha catalytic subunit that accommodates the nSH2 domain in the p85\alpha regulatory subunit, whose release from p110\textalpha is the key event initiating PI3K\textalpha activation. The kinase domain in the p110\textalpha subunit executes substrate catalysis. In PI3K\textalpha activation, it moves away from the C2 domain and becomes more accessible for membrane interactions.\textsuperscript{16} The transition from an inactive to an active state executes signal transduction.\textsuperscript{22}

A recent single molecule imaging study of PI3K\textalpha activation by a receptor and HRas on a supported lipid bilayer observed synergistic activation,\textsuperscript{24} with a mechanism resembling our mechanism with phosphorylated CaM substituting for the receptor.\textsuperscript{12,13} However, contrary to the prevailing notion that Ras activates PI3K, as it does its other effectors (Raf, RaIGDs, RASSF, and more), the authors observe that HRas binding inhibits PI3K\textalpha, inhibition which the authors suggest is overcome by the membrane recruitment. HRas promotes membrane density of P-y-activated PI3K\textalpha by ~20 fold but inhibit their activities by ~2 fold, which, in total, lead to a ~10-fold synergistic PI3K\textalpha activation.\textsuperscript{30}

Earlier we observed potential allosteric communication from HRas to Raf’s RBD;\textsuperscript{37} however, it is questionable whether Ras is allosterically involved in Raf’s activation given the long linker
extending from the RBD/CRD (cysteine-rich domain) to the kinase domain. Thus, as in PI3K, Ras activates Raf by recruiting it to membrane; however, Ras assists in relieving Raf’s autoinhibition not by allostery, but through high (nanomolar) binding affinity to Raf’s RBD. This binding shifts the equilibrium toward Raf’s open state, permitting dimerization and activation of the kinase domain. A similar membrane recruitment and equilibrium shift scenario was also suggested for tumor suppressor RASSF5, consistent with experimental observations. In PI3K the autoinhibition is relieved by the RTK’s phosphorylated motif. This difference between Raf and PI3K reflects their functions: PI3K is a lipid kinase. The kinase domain has to be at the membrane. In contrast, Raf is a protein kinase. The long linker permits binding the MEK/ERK dimer complexes away from the membrane. At the same time, Ras assists in Raf’s activation not only by recruiting the RBD to the membrane; but also, by restricting Raf’s CRD fluctuations and stabilizing productive RBD–CRD orientations, a role resembling its recruitment and restriction of the PI3Kα active state at the membrane.

Conclusions

Herein, we modeled the atomic structure of Ras binding to the PI3Kα, understanding the structural basis for PI3Kα activation by Ras. The structure presented excellent stability. The Ras–PI3Kα interface features antiparallel β-sheet interactions and residue contacts between the Switch I and II regions in Ras and PI3Kα. Mutations of key residues disrupted the Ras–PI3Kα interface, reproducing the experimental behavior. Ras isoforms have practically identical structures but with some distinctive sequences and conformational tendencies. Isomargin-specific residues are away from the KRas4B–RBD interface, suggesting that the KRas4B–RBD complex may represent a general Ras–PI3K activation scenario. The allosteric signaling pathways from KRas4B propagating to the RBD of PI3Kα appear an insignificant factor in PI3Kα activation. We favor a Ras role that involves PI3Kα recruitment to the membrane and assisting RTK in achieving full activation. RTKs act in relieving the PI3Kα autoinhibition via a conformational change that leads to exposure of the PI3K active site to the membrane, permitting thePIP2 substrate to bind there; however, it may not position and orient the kinase domain surface at a catalytically-favored state with respect to the membrane and the PIP2 substrate. Active Ras is at the membrane. Through binding to the PI3Kα RDB, it restricts the ensemble, thrusting it against the membrane in a PIP2-binding-favored state. Thus, even though RTKs can activate PI3K, coupling with Ras accomplishes full activation. The KRas4B–PI3Kα structure in this work sheds an atomistic-level light on how Ras activates PI3K and as such can offer the structural basis for the cancer drug discovery targeting the Ras–PI3Kα interactions.

Materials and methods

KRas4B–PI3Kα–RBD complex

The initial coordinates of PI3Kα (PDB code: 4OVV) and GTP-bound KRas4B (PDB code: 3GFT) were obtained from the protein data bank. We extracted the RBD from the full PI3Kα structure and modeled it with KRas4B-GTP. The KRas4B–PI3Kα–RBD complex was modeled with antiparallel β-sheet interactions. The residues in β2Ras and β2RBD were aligned with different residue matches to generate five models. Each generated KRas4B–RBD model contained three residue pairs with six backbone hydrogen bonds. To test the structural validity of our model, we performed explicit-solvent all-atom MD simulations for five model complexes and confirmed one (M3 model) with excellent stability. To enhance the sampling, eight additional simulations were performed for the confirmed M3 model of KRas4B–RBD complex with different initial atom velocities. For each system, 1 μs simulation was performed. Meanwhile, the simulations of the KRas4B–RBD complex (M3 model) with five mutations were individually performed to explore their roles in KRas4B–PI3Kα recognition, i.e., T208D, K210E, K227E, and R230E mutations in PI3Kα, and a G12D mutation in KRas4B. The modeled KRas4B–RBD interface was then used to model KRas4B into the full PI3Kα.

Simulation protocols

Production MD simulation runs were conducted by the NAMD package with the CHARMM all-atom additive force field (version C36). The NPT ensemble was controlled with the temperature of 310 K and pressure of 1 atm. The explicit TIP3 water model was used to solvate the systems in the isometric unit cell box. The system was neutralized by Na+ and Cl− ions, achieving a 0.15 mol L−1 ion concentration. Short-range van der Waals (vdW) and the long-rang electrostatic interactions were described by the switch function and the particle mesh Ewald (PME) algorithm. A time step of 2 fs was employed in the MD simulations. The allosteric pathways from KRas4B to PI3K’s RBD were calculated by the weighted implementation of suboptimal paths (WISP) algorithm. WISP algorithm identified the primary residue communication path. The allosteric pathways are between R41KRas4B to M278PI3Kα for the aligned KRas4B–RBD complexes in the trajectories. The visualization of allosteric pathway was performed by VMD software.

Author contributions

MZ, HJ, and RN conceived and designed the study. MZ conducted most of the simulations and analyzed the results. MZ, HJ, and RN wrote the paper.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This project has been funded in whole or in part with Federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract HHSN261200800001E. This research was supported (in part)
by the Intramural Research Program of NIH, Frederick National Lab, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the high-performance computational facilities of the Biowuilf PC/Linux cluster at the National Institutes of Health, Bethesda, MD, USA (https://hpc.nih.gov/).

References

1 O. Vadas, J. E. Burke, X. Zhang, A. Berndt and R. L. Williams, *Sci. Signaling*, 2011, 4, re2.

2 L. Stephens, R. Williams and P. Hawkins, *Curr. Opin. Pharmacol.*, 2005, 5, 357–365.

3 L. M. Thorpe, H. Yuzugulli and J. J. Zhao, *Nat. Rev. Cancer*, 2015, 15, 7–24.

4 E. H. Walker, O. Perisic, C. Ried, L. Stephens and R. L. Williams, *Nature*, 1999, 402, 313–320.

5 Y. Ito, J. R. Hart, L. Ueno and P. K. Vogt, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, 111, 16826–16829.

6 M. S. Lawrence, P. Stojanov, C. H. Mermel, J. T. Robinson, L. A. Garraway, T. R. Golub, M. Meyerson, S. B. Gabriel, E. S. Lander and G. Getz, *Nature*, 2014, 505, 495–501.

7 L. M. Thorpe, J. M. Spangle, C. E. Ohlson, H. Cheng, T. M. Roberts, L. C. Cantley and J. J. Zhao, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, 114, 7095–7100.

8 J. Yu, C. Wjasow and J. M. Backer, *J. Biol. Chem.*, 1998, 273, 30199–30203.

9 J. E. Burke, O. Perisic, G. R. Masson, O. Vadas and R. L. Williams, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, 109, 15259–15264.

10 R. T. Nolte, M. J. Eck, J. Schlessinger, S. E. Shoeelson and S. C. Harrison, *Nat. Struct. Biol.*, 1996, 3, 364–374.

11 S. B. Gabelli, I. Echeverria, M. Alexander, K. C. Duong-Ly, D. Chaves-Moreira, E. T. Brower, B. Vogelstein and L. M. Amzel, *Biophys. Rev.*, 2014, 6, 89–95.

12 M. Zhang, Z. Li, G. Wang, H. Jang, D. B. Sacks, J. Zhang, V. Gaponenko and R. Nussinov, *J. Phys. Chem. B*, 2018, 122(49), 11137–11146.

13 M. Zhang, H. Jang, V. Gaponenko and R. Nussinov, *Biophys. J.*, 2017, 113, 1956–1967.

14 J. L. Joyal, D. J. Burks, S. Pons, W. F. Matter, C. J. Vlahos, M. F. White and D. B. Sacks, *J. Biol. Chem.*, 1997, 272, 28183–28186.

15 W. C. Hon, A. Berndt and R. L. Williams, *Oncogene*, 2012, 31, 3655–3666.

16 M. Zhang, H. Jang and R. Nussinov, *Chem. Sci.*, 2019, 10, 3671–3680.

17 E. Castellano and J. Downward, *Genes Cancer*, 2011, 2, 261–274.

18 M. M. Murillo, S. Zelenay, E. Nye, E. Castellano, F. Lassailly, G. Stamp and J. Downward, *J. Clin. Invest.*, 2014, 124, 3601–3611.

19 K. Tsutsumi, Y. Fujioka, M. Tsuda, H. Kawaguchi and Y. Ohba, *Cell. Signalling*, 2009, 21, 1672–1679.

20 J. Wang, Y. Yuan, Y. Zhou, L. Guo, L. Zhang, X. Kuai, B. Deng, Z. Pan, D. Li and F. He, *J. Proteome Res.*, 2008, 7, 3879–3889.

21 R. Nussinov, C. J. Tsai and H. Jang, *Semin. Cancer Biol.*, 2018, 54, 109–113.

22 T. S. Chavan, H. Jang, L. Khavrutskii, S. J. Abraham, A. Banerjee, B. C. Freed, L. Johannessen, S. G. Tarasov, V. Gaponenko, R. Nussinov and N. I. Tarasova, *Biophys. J.*, 2015, 109, 2602–2613.

23 H. Jang, A. Banerjee, T. S. Chavan, S. Lu, J. Zhang, V. Gaponenko and R. Nussinov, *FASEB J.*, 2016, 30, 1643–1655.

24 T. C. Buckles, B. P. Ziemia, G. R. Masson, R. L. Williams and J. J. Falke, *Biophys. J.*, 2017, 113, 2396–2405.

25 H. Jang, A. Banerjee, T. Chavan, V. Gaponenko and R. Nussinov, *J. Biol. Chem.*, 2017, 292, 12544–12559.

26 H. Jang, S. J. Abraham, T. S. Chavan, B. Hitchinson, L. Khavrutskii, N. I. Tarasova, R. Nussinov and V. Gaponenko, *J. Biol. Chem.*, 2015, 290, 9465–9477.

27 D. Abankwa, A. A. Gorfe, K. Inder and J. F. Hancock, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, 107, 1130–1135.

28 R. Nussinov, C. J. Tsai and H. Jang, *Cancer Res.*, 2018, 78, 593–602.

29 A. Banerjee, H. Jang, R. Nussinov and V. Gaponenko, *Curr. Opin. Struct. Biol.*, 2016, 36, 10–17.

30 T. C. Buckles, B. P. Ziemia, G. R. Masson, R. L. Williams and J. J. Falke, *Biophys. J.*, 2017, 113, 2396–2405.

31 M. E. Pacold, S. Suire, O. Perisic, S. Lara-Gonzalez, C. T. Davis, E. H. Walker, P. T. Hawkins, L. Stephens, J. F. Eccleston and R. L. Williams, *Cell*, 2000, 103, 931–943.

32 S. Gupta, A. R. Ramjaun, P. Haiko, Y. Wang, P. H. Warne, B. Nicke, E. Nye, G. Stamp, K. Alitalo and J. Downward, *Cell*, 2007, 129, 957–968.

33 P. Rodriguez-Viciana, P. H. Warne, B. Vanhaesebroeck, M. D. Waterfield and J. Downward, *EMBO J.*, 1996, 15, 2442–2451.

34 R. Nussinov, C. J. Tsai and H. Jang, *Semin. Cancer Biol.*, 2018, 54, 114–120.

35 R. Nussinov, M. Zhang, C. J. Tsai, T. J. Liao, D. Fushman and H. Jang, *Biophys. Rev.*, 2018, 10, 1263–1282.

36 I. M. Ahearn, K. Haigis, D. Bar-Sagi and M. R. Philips, *Nat. Rev. Mol. Cell Biol.*, 2011, 13, 39–51.

37 S. K. Fetics, H. Gutерres, B. M. Kearney, G. Bhurman, B. Ma, R. Nussinov and C. Mattos, *Structure*, 2015, 23, 505–516.

38 L. Huang, F. Hofer, G. S. Martin and S. H. Kim, *Nat. Struct. Biol.*, 1998, 5, 422–426.

39 A. T. Van Vart, J. Durrant, L. Votapka and R. E. Amaro, *J. Chem. Theory Comput.*, 2014, 10, 511–517.

40 L. C. Chang, H. M. Chiu, C. T. Shun, J. T. Liang, J. T. Lin, C. C. Chen, Y. C. Lee and M. S. Wu, *BMC Gastroenterol.*, 2014, 14, 221.

41 N. Miled, Y. Yan, C. J. Vlahos, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H. J. Wolfson, J. M. Backer and R. L. Williams, *Science*, 2007, 317, 239–242.

42 L. Zhao and P. K. Vogt, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, 105, 2652–2657.

43 T. Pantsar, S. Rissanen, D. Dauch, T. Laitinen, I. Vattulainen and A. Poso, *PLoS Comput. Biol.*, 2018, 14(9), e1006458.
44 T. K. Owonikoko and F. R. Khuri, *American Society of Clinical Oncology Educational Book*, 2013.

45 E. Pons-Tostivint, B. Thibault and J. Guillermet-Guibert, *Trends Cancer*, 2017, 3, 454–469.

46 R. Nussinov, C. J. Tsai, M. Chakrabarti and H. Jang, *Cancer Res.*, 2016, 76, 18–23.

47 P. Rodriguez-Viciana, P. H. Warne, R. Dhand, B. Vanhaesebroeck, I. Gout, M. J. Fry, M. D. Waterfield and J. Downward, *Nature*, 1994, 370, 527–532.

48 R. Nussinov, G. Wang, C. J. Tsai, H. Jang, S. Lu, A. Banerjee, J. Zhang and V. Gaponenko, *Trends Cancer*, 2017, 3, 214–224.

49 R. Nussinov, S. Muratcioglu, C. J. Tsai, H. Jang, A. Gursoy and O. Keskin, *Expert Opin. Ther. Targets*, 2016, 20, 831–842.

50 R. Nussinov, C. J. Tsai, S. Muratcioglu, H. Jang, A. Gursoy and O. Keskin, *Expert Rev. Proteomics*, 2015, 12, 669–682.

51 R. Nussinov, H. Jang, C. J. Tsai, T. J. Liao, S. Li, D. Fushman and J. Zhang, *Cell. Mol. Life Sci.*, 2017, 74, 3245–3261.

52 R. Nussinov, C. J. Tsai and H. Jang, *Expert Rev. Proteomics*, 2016, 13, 711–716.

53 R. Nussinov and C. J. Tsai, *Cell*, 2013, 153, 293–305.

54 G. A. Hobbs, C. J. Der and K. L. Rossman, *J. Cell Sci.*, 2016, 129, 1287–1292.

55 J. A. Engelman, L. Chen, X. Tan, K. Crosby, A. R. Guimaraes, R. Upadhyay, M. Maira, K. McNamara, S. A. Perera, Y. Song, L. R. Chirieac, R. Kaur, A. Lightbown, J. Simendinger, T. Li, R. F. Padera, C. Garcia-Echeverria, R. Weissleder, U. Mahmood, L. C. Cantley and K. K. Wong, *Nat. Med.*, 2008, 14, 1351–1356.

56 H. Y. Fan, M. Shimada, Z. Liu, N. Cahill, N. Noma, Y. Wu, J. Gossen and J. S. Richards, *Development*, 2008, 135, 2127–2137.

57 S. Lu, H. Jang, S. Muratcioglu, A. Gursoy, O. Keskin, R. Nussinov and J. Zhang, *Chem. Rev.*, 2016, 116, 6607–6665.

58 S. Lu, H. Jang, S. Gu, J. Zhang and R. Nussinov, *Chem. Soc. Rev.*, 2016, 45, 4929–4952.

59 S. Lu, H. Jang, J. Zhang and R. Nussinov, *Phys. Chem. Chem. Phys.*, 2017, 19, 6470–6480.

60 T. J. Liao, C. J. Tsai, H. Jang, D. Fushman and R. Nussinov, *Curr. Opin. Struct. Biol.*, 2016, 41, 217–224.

61 R. Nussinov, G. Wang, C. J. Tsai, H. Jang, S. Lu, A. Banerjee, J. Zhang and V. Gaponenko, *Trends Cancer*, 2017, 3, 214–224.

62 R. Nussinov, S. Muratcioglu, C. J. Tsai, H. Jang, A. Gursoy and O. Keskin, *Expert Opin. Ther. Targets*, 2016, 20, 831–842.

63 R. Nussinov, C. J. Tsai, S. Muratcioglu, H. Jang, A. Gursoy and O. Keskin, *Expert Rev. Proteomics*, 2015, 12, 669–682.

64 R. Nussinov, H. Jang, C. J. Tsai, T. J. Liao, S. Li, D. Fushman and J. Zhang, *Cell. Mol. Life Sci.*, 2017, 74, 3245–3261.

65 R. Nussinov, C. J. Tsai and H. Jang, *Expert Rev. Proteomics*, 2016, 13, 711–716.

66 R. Nussinov and C. J. Tsai, *Cell*, 2013, 153, 293–305.

67 G. A. Hobbs, C. J. Der and K. L. Rossman, *J. Cell Sci.*, 2016, 129, 1287–1292.

68 J. A. Engelman, L. Chen, X. Tan, K. Crosby, A. R. Guimaraes, R. Upadhyay, M. Maira, K. McNamara, S. A. Perera, Y. Song, L. R. Chirieac, R. Kaur, A. Lightbown, J. Simendinger, T. Li, R. F. Padera, C. Garcia-Echeverria, R. Weissleder, U. Mahmood, L. C. Cantley and K. K. Wong, *Nat. Med.*, 2008, 14, 1351–1356.